HELP FOR ADDICTION to opioids
THE FUTURE OF ADDICTION RELIEF
When someone you love is suffering where can you turn?
Treatment of withdrawal symptoms from drug addiction using TCES.
A message of hope and inspiration for everyone involved in the treatment of opiate addiction.
Transcutaneous Cranial Electrical Stimulation (TCES) involves painlessly applying balanced current pulses to the head through three electrodes.The main property of the Limoge TCES device is to potentiate some drug effects.
Over a period of 10 years Dr. Limoge and his team treated 4 thousand heroin and morphine addicts. Because the results were so promising and in order to quantify the study, Dr. Limoge and his staff randomly selected 160 case files for analysis.
Futramed Inc. is currently seeking investors for the Limoge TCES medical device. With your help we can provide affordable solutions for all individuals suffering from pain, substance abuse, and other physical and behavioral limitations.
TO STABILIZE, REDUCE, OR REPLACE DOSAGES OF OPIOIDS used to treat patients suffering with pain; and reduce the symptoms of patients experiencing Opiate Withdrawal Syndrome (OWS).
FutraMed Inc. was founded in the state of Utah in the United States to create and apply technology to provide affordable solutions for all individuals suffering from pain, substance abuse, and other physical and behavioral limitations.
With the consumption of painkillers soaring in the United States and throughout the world, FutraMed has developed a patented medical device that has clinical benefits which include reducing opioid consumption and dependence in the treatment of pain.
The technology for the device, a transcutaneous electrical cranial stimulator, is based on the work of Dr. Aimé Limoge of Paris, France and the Limoge Current which he developed. The Limoge Current creates an analgesic effect and potentiates or enhances the treatment drug being used by the chronic pain patient. In collaboration with Dr. Limoge and his associates, the FutraMed team was able to effectively replicate the Limoge Current and create a device that is simple to use, low cost, battery powered, meets regulatory requirements, and is easy to manufacture.
CE Mark Certification granted in 2020 which allows for the commercialization of the TCES Device across the European Union and other CE Mark geographies.
U.S. Patent Approved
Not yet authorized for sale in the USA